Rapid multiplexed detection of beta-amyloid and total-tau as biomarkers for Alzheimer's disease in cerebrospinal fluid

Nanomedicine. 2018 Aug;14(6):1845-1852. doi: 10.1016/j.nano.2018.05.013. Epub 2018 May 29.

Abstract

This paper reports the multiplexed monitoring of two promising biomarkers, beta-amyloid (Aβ42) and total tau (T-tau), in both buffer and cerebrospinal fluid (CSF) for Alzheimer's disease (AD) using label-free optical nanosensors. It has been found that 7.8 pg/ml of Aβ42 in buffer and 15.6 pg/ml of T-au in buffer can be readily detected with very good specificity. Based on our measurements, the purchased CSF itself contains Aβ42, whose concentration is estimated to be about 400 pg/ml. Aβ42 and T-tau in the mixtures of Aβ42 and T-tau spiked in CSF have been detected successfully, indicating the feasibility of the optical nanosensors to detect these biomarkers in clinical samples. For the measurements, only a small amount (~1 μl) of the samples is required. This type of sensor is suitable for point-of-care application to diagnose the AD due to its low cost and ease-of-operation.

Keywords: Alzheimer's disease; Biomarker; Cerebrospinal fluid; Multiplexed detection; Nanosensors.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aluminum Oxide / chemistry*
  • Alzheimer Disease / cerebrospinal fluid*
  • Alzheimer Disease / diagnosis*
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Biomarkers / cerebrospinal fluid*
  • Biosensing Techniques
  • Electrodes
  • Female
  • Humans
  • Male
  • Middle Aged
  • Young Adult
  • tau Proteins / cerebrospinal fluid*

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • MAPT protein, human
  • tau Proteins
  • Aluminum Oxide